GSK PLC’s Revenue by Segment (2016-2023)

This statistic highlights GSK PLC’s Revenue by Segment, split between Commercial operations, Consumer Healthcare, Pharmaceuticals and Vaccines, reported quarterly from Q1 2016 onwards.

GSK PLC’s Revenue by Segment

(All figures in £)

GSK operates in three primary segments: Commercial Operations, Consumer Healthcare (deprecated), and Pharmaceuticals. These segments form GSK’s diverse product portfolio and play a significant role in generating the company’s revenue.

Commercial Operations

Commercial Operations represent GSK’s commercial activities in various regions. In Q1 2023, this segment recorded a revenue of £6.93 billion, which increased to £7.83 billion in Q2, showing a quarter-on-quarter growth rate of approximately 12.97%.

Consumer Healthcare

Consumer Healthcare, once included in financial reporting, is no longer considered relevant or actively tracked. In Q1 2022, Consumer Healthcare generated £2,633,000,000.0 in financial figures. It used to cover over-the-counter medicines, personal care products, and other healthcare items for consumers. The term “deprecated” indicates that this category is no longer used or reported in financial information. Although the Consumer Healthcare segment is being separated from GSK, historically, it was a significant contributor to the company’s revenue.

Pharmaceuticals

Pharmaceuticals, representing GSK’s prescription medicines, has been deprecated since 2022. In Q1 2022, this segment’s revenue was £5.47 billion. The decline in revenue and commercial operations in this category reflects potential challenges faced by the pharmaceutical industry, such as patent expirations, generic competition, or shifts in consumer preferences. Companies in this sector might have shifted their focus to other segments or strategies to adapt to changing market dynamics. The data suggests that the pharmaceutical industry’s performance has been affected, leading to its deprecation in financial reports.

GSK’s revenue is well diversified across its different segments, providing a balanced portfolio and reducing dependence on any single business area. This diversification strategy enables GSK to navigate market fluctuations and capitalize on opportunities in various therapeutic markets and geographical regions. Several factors influence GSK’s revenue growth, including product launches, patent expirations, pricing strategies, regulatory approvals, and market competition. Additionally, GSK’s commitment to research and development, investment in innovation, and strategic partnerships contribute to revenue growth and enhance the company’s competitive position.

Vaccines

Vaccines segment of GSK PLC has has been deprecated since 2022 or is no longer considered relevant or actively tracked. In the Q1 2022, this segment’s revenue was £ 1,669,000,000.0.

About GSK PLC

GSK PLC, also known as GlaxoSmithKline, is a renowned global pharmaceutical and healthcare company established in the year 2000. Their primary focus is on creating and manufacturing innovative prescription medications, vaccines, and consumer healthcare products. GSK is driven by a mission to enhance people’s lives by delivering high-quality healthcare solutions, helping them do more, feel better, and live longer. They cater to patients and consumers worldwide, addressing diverse medical needs, ranging from treating infectious diseases to offering over-the-counter remedies for everyday health concerns. GSK’s wide-ranging portfolio and unwavering commitment to scientific research and development empower them to have a positive impact on the health and well-being of individuals and communities across the globe.

Did you like GSK PLC’s Revenue by Segment statistic?

Access more such KPI data points and segment financials on thousands of US stocks, with Business Quant.

You can get started here.